How Mutant p53 Hijacks VWF Expression in Tumor Cells – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Noorossadat Seyyedi et al., adding:
”The role of mutant p53R175H in de novo activation of von Willebrand factor expression in tumor cells
Von Willebrand factor is normally made only by endothelial cells and megakaryocytes, yet some cancers switch it on.
Across 100 VWF-positive cancer lines, this study tied that aberrant expression to the mutant p53R175H, which engages the repressor NF-IB and activator GATA6 to drive VWF from the promoter.
The resulting VWF fueled cancer cell to platelet aggregates, and plakoglobin reversed the effect.”
Title: The role of mutant p53R175H in de novo activation of von Willebrand factor expression in tumor cells
Authors: Noorossadat Seyyedi, Chu Shiun Lo, Parnian Alavi, Manijeh Pasdar, Nadia Jahroudi
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning